Edition:
Deutschland

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

222.50USD
18:03 Uhr
Change (% chg)

$0.10 (+0.04%)
Prev Close
$222.40
Open
$222.70
Day's High
$222.80
Day's Low
$222.35
Volume
75,266
Avg. Vol
252,274
52-wk High
$223.96
52-wk Low
$42.75

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Buy/Sell

Sell Hold Buy
3.00 Mean rating from 9 analysts

Overall

Beta: 2.11
Market Cap(Mil.): $11,855.85
Shares Outstanding(Mil.): 53.31
Dividend: --
Yield (%): --

US STOCKS-Wall St jumps on stimulus hopes, hints of Trump's return to White House

* Doctors to weigh if Trump can leave hospital Monday - Trump aide

Photo

Bristol Myers expands heart drug business with $13 bln deal for MyoKardia

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

Photo

Bristol Myers expands heart drug business with $13 billion deal for MyoKardia

Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

UPDATE 3-Bristol Myers expands heart drug business with $13 bln deal for MyoKardia

Oct 5 Bristol Myers Squibb Co said on Monday it would buy MyoKardia Inc for about $13 billion to bolster its portfolio of heart disease treatments, ahead of the potential loss of sales exclusivity of some of its blockbuster drugs.

US STOCKS-Wall St jumps on stimulus hopes, hints of Trump's return to White House

* Doctors to weigh if Trump can leave hospital Monday - Trump aide

US STOCKS-Wall St set to jump on stimulus hopes, hints of Trump hospital discharge

* Futures up: Dow 0.75%, S&P 0.64%, Nasdaq 0.72% (Adds comments; updates prices)

Bristol-Myers to buy heart drugs developer MyoKardia for about $13 bln

Oct 5 U.S. drugmaker Bristol-Myers Squibb Co said on Monday it would buy heart drugs developer MyoKardia Inc for about $13 billion.

BRIEF-Myokardia Announces Appointment Of Denelle J. Waynick As General Counsel And Corporate Secretary

* MYOKARDIA ANNOUNCES APPOINTMENT OF DENELLE J. WAYNICK AS GENERAL COUNSEL AND CORPORATE SECRETARY Source text for Eikon: Further company coverage:

BRIEF-Myokardia Inc - Plans To Start Phase 2 Genetic Dcm Study In Second Half Of 2020

* MYOKARDIA ANNOUNCES POSITIVE DATA FROM PHASE 2A CLINICAL TRIAL OF DANICAMTIV PRESENTED AT ESC’S HFA DISCOVERIES WITH SIMULTANEOUS PUBLICATION IN EUROPEAN JOURNAL OF HEART FAILURE

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.75%
Rohstoffe -0.34%
Industrie -0.46%
Konjunktur abhängige Waren & Dienstleistungen -0.28%
Konjunktur unabhängige Waren & Dienstleistungen +0.80%
Finanzindustrie +0.53%
Pharma -0.80%
Technologie +0.00%